Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
5
×
boston blog main
boston top stories
drugs
5
×
life sciences
national blog main
clinical trials
fda
alnylam pharmaceuticals
national top stories
new york blog main
new york top stories
patisiran
akcea therapeutics
hereditary transthyretin amyloidosis
inotersen
onpattro
rna interference
san diego blog main
san diego top stories
tafamidis
acute hepatic porphyrias
akin akinc
aldehyde
aldeyra therapeutics
allergic conjunctivitis
allopregnanolone
aminolevulinic acid
barry greene
biotech
boston university
brexanolone
dan ollendorf
dry eye disease
european medicines agency
givosiran
harvard pilgrim health care
institute for clinical and economic review
john berk
marc goodman
What
fda
5
×
medicine
drug
alnylam
rna
ago
interference
new
rnai
uses
aldeyra
approval
approve
approved
approves
awaits
biological
brexanolone
cells
closer
crossed
data
decades
decision
depression
devastating
disclosed
discovered
disorder
ema
employ
europe
eye
fast
fighting
filing
fingers
follows
friday
gene
Language
Current search:
drugs
×
boston
×
fda
×
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision